Biotech Values

[mcbio]

The future of HCV oral therapy, if successful, is the second generation Sofo/GS-5816 combo. One pill, Once-a-day, without ribavirin, and that works for all HCV patients.

While in theory, if it pans out down the road, that combo may well work in many more possible patients, that still to me doesn't preclude other potent QD combos from competing in GTs where the latter successfully work. And I suspect there will still be room to compete on price in these individual GTs against the Sofo/GS-5816 combo.